Dr Karen Tiley PhD, MSc, MA (Cantab)

Dr Karen Tiley

Department of Applied Health Sciences
Research Fellow (Epidemiology)

Contact details

Address
School of Health Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Karen’s current research focuses on estimating the incidence of neonatal infections including Klebsiella pneumoniae, Escherichia coli and group B Streptococcus (GBS).

Her wider research interests include seroepidemiology, correlates of protection, and pneumococcal carriage and disease.

Qualifications

  • PhD in Epidemiology, Manchester Metropolitan University, 2015
  • MSc in Epidemiology, Imperial College, London, 2004
  • MA (Cantab) in Natural Sciences (Biological), University of Cambridge, 2002

Biography

Karen studied Natural Sciences at the University of Cambridge, specialising in microbiology and parasitology, before completing an MSc in Epidemiology at Imperial College, London.

She joined the Health Protection Agency (now the UK Health Security Agency) in 2005 and worked across several areas, including healthcare-associated infections, travel and migrant health, and immunisation. She also spent a year at the London School of Hygiene & Tropical Medicine in 2009–2010, working in maternal health. During her time at the Health Protection Agency, Karen completed a PhD by publication studying the epidemiology of diphtheria in the UK and Europe.

In September 2020, Karen joined the Oxford Vaccine Group at the University of Oxford, initially working on a maternal-infant measles seroprevalence study. Her subsequent research focused on serology and carriage studies, particularly in relation to measles and pneumococcal disease.

Karen joined the School of Health Sciences at the University of Birmingham in 2026.

Postgraduate supervision

Karen is interested in supervising doctoral students in the following areas:

  • Epidemiology of neonatal infections
  • Seroepidemiology
  • Correlates of protection

Research

Karen is the Principal Investigator of a Gates-funded study estimating the incidence of neonatal Klebsiella pneumoniae and Escherichia coli infections by gestational age. The study aims to provide evidence to inform the optimal timing and design of maternal vaccination trials.